这是描述信息
Location:
Homepage
/
/
Hongqi Pharmaceutical participated in a series of reports on the National Tuberculosis Academic Conference (3) Carrying on the past, and setting sail --- The 2017 National Tuberculosis Academic Conference came to a successful conclusion

Hongqi Pharmaceutical participated in a series of reports on the National Tuberculosis Academic Conference (3) Carrying on the past, and setting sail --- The 2017 National Tuberculosis Academic Conference came to a successful conclusion

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2017-06-06
  • Views:0

(Summary description)On May 27, the 2017 National Tuberculosis Academic Conference and the 80th Anniversary of the Founding of Tuberculosis Branch came to a perfect conclusion.

Hongqi Pharmaceutical participated in a series of reports on the National Tuberculosis Academic Conference (3) Carrying on the past, and setting sail --- The 2017 National Tuberculosis Academic Conference came to a successful conclusion

(Summary description)On May 27, the 2017 National Tuberculosis Academic Conference and the 80th Anniversary of the Founding of Tuberculosis Branch came to a perfect conclusion.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2017-06-06
  • Views:0
Information
  On May 27, the 2017 National Tuberculosis Academic Conference and the 80th Anniversary of the Founding of Tuberculosis Branch came to a perfect conclusion. There were more than 2,100 delegates participating in the conference, from 571 institutions in 34 provinces (municipalities, autonomous regions) across the country, including 461 medical institutions and 85 disease control centers and prevention centers. It is worth mentioning that 83 county (district)-level primary tuberculosis diagnosis and treatment, prevention and treatment institutions sent personnel to participate in the conference.
  The Xianglu Hall at the closing ceremony was full of seats, and everyone cherished this last time together. During the conference, it was full of passion and touch, and was permeated with a strong academic atmosphere. The closing ceremony was presided over by Li Liang, vice president of Beijing Chest Hospital affiliated to Capital Medical University, the chairman-elect of the branch.
 
 
  The content of this conference is rich and exciting. A total of 1 plenary conference, 1 pre-conference training, 1 youth forum, 1 nursing forum, 12 special reports in different professional fields, 9 satellite conferences, and 3 special exchanges were opened. At the meeting, a total of 187 experts conducted academic exchanges at different venues, and also invited experts from the United States and Japan to give reports. According to statistics, the conference received a total of 83 submissions and a total of 535 articles, including 179 articles on clinical diagnosis and treatment, 47 articles on surgery, 17 articles on intervention, 23 articles on imaging, 132 articles on basic and laboratory studies, 29 articles on prevention, and 108 articles on nursing. The conference academic committee selected 16 excellent papers (including 2 nursing professional papers). The conference selected 16 excellent paper awards, 12 excellent organization units, 10 gold partners, and awarded 5 Best Propaganda Awards and 13 Mass Communication Awards in the 324 TB Knowledge Propaganda Competition of Hundred Hospitals in the Union Cup.
  Finally, Chairman-designate Li Liang announced that the 2018 National Academic Conference will be held in Taiyuan, Shanxi. With the flag passing from Zheng Chao, Dean of Xinglin Branch of the First Affiliated Hospital of Xiamen University to Dong Yongkang, Vice Dean of Taiyuan Fourth People's Hospital, the 2017 National Academic Conference officially came to an end.
  2017 is an important year for the implementation of the "13th Five-Year Plan" and a year for deepening medical reform to overcome difficulties. As of 2017, the Tuberculosis Branch has gone through 80 years of ups and downs and has played an important role in the prevention and treatment of tuberculosis in my country. In the 80 years since its founding, the Tuberculosis Branch has consistently held high the banner of business development and talent training, and has carried out a lot of work in the clinical diagnosis and control of tuberculosis. The Tuberculosis Branch always attaches great importance to the cultivation of talents, and the past directors have made talent cultivation one of the key tasks. At the annual meeting of the Tuberculosis Branch, it is to create opportunities for young people. Thanks to the efforts of the Tuberculosis Branch, in recent years, a large number of young talents have grown rapidly and become the backbone of the discipline, which also brings hope and vitality to the future development of the Tuberculosis Branch.
  Shenyang Hongqi Pharmaceutical Co., Ltd. was awarded one of the top ten gold partners. On May 25, Hongqi Pharmaceuticals cooperated with the Innovation Alliance and the Tuberculosis Branch for the first time and jointly signed a major talent training project-the "Young Eagle" project. Mr. Li Shaowei, general manager of the sales department of Hongqi Pharmaceuticals, took the stage to receive the award.
 
 
  After 80 years, the Tuberculosis Branch is in its youth and full of vitality. We are deeply honored to sign the "Eagle" project. With mission and responsibility, we continue to follow the footsteps of our predecessors. Under the leadership of the Tuberculosis Branch, Hongqi Pharmaceutical inherits the past and the future, and sets sail. Just like our theme of this conference, "Inheritance and Innovation", we must actively face the new situation and new challenges based on the summary of the successful experience of the past work, unite and strengthen cooperation. Support each other to effectively curb the tuberculosis epidemic in our country, benefit the broad masses of people, and make greater contributions to ending the tuberculosis epidemic.
  As the country's largest anti-tuberculosis drug R&D and production base, Hongqi Pharmaceutical has made important contributions to the cause of China's tuberculosis defense. At present, its first-line anti-tuberculosis drugs are Rifampicin Capsules, Rifampicin Capsules II, Isoniazid Tablets, Ethambutol Tablets (Capsules), Pyrazinamide Tablets (Capsules), Prothionamide Enteric-coated Tablets, etc. Sales have always been in the forefront of the country. In particular, FDC (Fixed Dose Combination) products have two kinds of medicines taken daily and every other day. At present, Hongqi Pharmaceutical's anti-tuberculosis drugs have been serialized. Under the background of China's establishment and improvement of a new type of tuberculosis prevention and treatment system, Hongqi Pharmaceutical will innovate more good products and make greater contributions to the cause of China's tuberculosis defense.

Scan the QR code to read on your phone

Copyright hongqipharma.com All rights reserved     Powered by:300.cn Shenyang    辽icp备12005917号    (辽)-非经营性-2018-0012 

Add:Shenyang Hunnan New District envelope 6th Street    Tel:024-23786268-8012  Fax:024-23786263